MARTINA, Valentino
 Distribuzione geografica
Continente #
NA - Nord America 1.165
EU - Europa 941
AS - Asia 423
AF - Africa 52
OC - Oceania 3
SA - Sud America 1
Totale 2.585
Nazione #
US - Stati Uniti d'America 1.154
CN - Cina 318
IE - Irlanda 139
SE - Svezia 138
UA - Ucraina 135
IT - Italia 127
FR - Francia 103
FI - Finlandia 86
KR - Corea 83
DE - Germania 79
SN - Senegal 47
GB - Regno Unito 45
PL - Polonia 34
AT - Austria 29
BE - Belgio 13
CA - Canada 11
VN - Vietnam 9
GR - Grecia 6
SG - Singapore 6
MU - Mauritius 4
AU - Australia 3
ES - Italia 3
IN - India 3
AL - Albania 1
AM - Armenia 1
BR - Brasile 1
DZ - Algeria 1
NL - Olanda 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
RU - Federazione Russa 1
UZ - Uzbekistan 1
Totale 2.585
Città #
Beijing 279
Chandler 220
Houston 150
Dublin 139
Villeurbanne 70
Jacksonville 64
Ann Arbor 60
Dearborn 60
Princeton 57
Ashburn 56
Nyköping 45
Medford 42
Warsaw 32
Milan 29
Vienna 29
Wilmington 29
Boston 20
Boardman 16
Verona 13
Torino 12
Brussels 11
Detroit 9
Norwalk 9
Woodbridge 9
Fairfield 8
Fremont 8
Washington 8
Kunming 7
Hefei 6
Toronto 6
Dong Ket 5
Falls Church 5
Lachine 5
Mountain View 5
Rome 5
Nanjing 4
Redwood City 4
San Mateo 4
Chicago 3
Jinan 3
Singapore 3
Gent 2
Guangzhou 2
Kraków 2
Philadelphia 2
Pune 2
Shanghai 2
Shenyang 2
Silver Spring 2
Alghero 1
Ambrogio 1
Augusta 1
Ballabio 1
Bari 1
Brescia 1
Cagliari 1
Cambridge 1
Castiglione D'adda 1
Denver 1
Des Moines 1
Edinburgh 1
Forlì 1
Fuzhou 1
Guiyang 1
Hangzhou 1
Hebei 1
Los Angeles 1
Maddaloni 1
Milazzo 1
Moncalieri 1
Nanchang 1
Ningbo 1
Oslo 1
Purley 1
Quzhou 1
Ramallah 1
Redcar 1
Redmond 1
Salerno 1
San Marcello 1
Seattle 1
Strasbourg 1
São Paulo 1
Taizhou 1
Tappahannock 1
Tarcento 1
Tiranë 1
Villasor 1
Wenzhou 1
West Palm Beach 1
Yerevan 1
Zhengzhou 1
Totale 1.608
Nome #
Nel soggetto normale la ferritemia correla con l’HOMA. 110
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans 106
Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus. 103
Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus. 102
Pirenzepine decreases basal and stimulated GH secretion in patients with type 2 (non-insulin-dependent) diabetes mellitus. 102
Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. 101
Comparison of Monotard and Ultratard insulin at bedtime in a model of optimized insulin therapy in Italy. 96
The altered plasma amino acid pattern is responsible for the paradoxical growth hormone response to the oral glucose tolerance test in liver cirrhosis. 86
Interaction of free fatty acids and arginine on growth hormone secretion in man. 81
Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences 78
Clinical and genetic variability in XX sex-reversed patients. 75
GHRELIN SECRETION IS INHIBITED BY GLUCOSE LOAD AND INSULIN-INDUCED HYPOGLYCEMIA BUT UNAFFECTED BY GLUCAGON AND ARGININE IN HUMANS 72
Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes. 70
Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus. 70
N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with type 2 diabetes mellitus 70
FEMALE PATIENTS WITH DOWN SYNDROME (DS) SHOW A GREATER INSULIN RESISTANCE IN COMPARISON WITH NORMAL FEMALES (NF) 70
L-Arginine 64
Dehydroepiandrosterone positively affects nitric oxide production in platelets of normal subjects. 64
PATIENTS WITH DOWN’S SYNDROME (DS) ARE INSULIN RESISTANT INDEPENDENTLY OF BODY MASS INDEX (BMI) 62
Bone metabolism in type 2 diabetes mellitus 61
Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1. 59
DHEAS and platelet cGMP variations during lifespan. 56
Platelet cGMP inversely correlates with age in healthy subjects. 55
Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects 54
Platelet cGMP inversely correlates with age in healthy subjects 53
Deydroepiandrosterone positevely affects nitric oxide production in the platelets of normal subjects. 53
Serum DHEAS levels correlate with platelet cGMP in normal women 51
In normal subjects HOMA positively correlates with serum ferritin, a cardiovascular risk factor. 51
I livelli plasmatici di dHEAS influenzano la produzione di cGMP piastrinico nel soggetto normale e nel soggetto affetto da DM T2. 50
METABOLIC ACTIONS OF GHRELIN 50
La ferritinemia: possibile marker di insulino resistenza. 48
Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. 47
La produzione di ossido nitrico si riduce con l’età e correla con il DHEAS e l’IGF-I nel soggetto normale. 47
Multiple endocrine neoplasia (MEN IIB) with Cushing's syndrome due to medullary thyroid carcinoma producing corticotropin-releasing hormone. 46
Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome 43
Platelet cyclic guanosine monophosphate production during menstrual cycle in healthy women. 42
Platelet cNOS activity is reduced in patients with IDDM and NIDDM. 39
Plasma DHEAS levels affect the platelet cGMP in normal subjects and in diabetic type 2 patients. 39
Role of the Decreased Nitric Oxide Bioavailability in the Vascular Complications of Diabetes Mellitus. 36
Transdermal oestradiol replacement therapy enhances platelet constitutive nitric oxide synthase activity in postmenopausal women with type 2 diabetes mellitus. 35
Plasma DHEAS levels affects the intraplatelet cGMP synthesis in normal subjects and in diabetic type 2 patients. 30
N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with Type 2 diabetes mellitus 29
Nitric Oxide production declines with age and correlates with DHEAS and IGF-1 in normal man. 27
Totale 2.683
Categoria #
all - tutte 7.840
article - articoli 0
book - libri 0
conference - conferenze 2.514
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.354


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201932 0 0 0 0 0 0 0 0 0 0 25 7
2019/2020402 3 4 17 28 41 153 69 13 25 18 24 7
2020/2021261 44 8 34 6 40 7 25 5 31 29 10 22
2021/2022301 5 5 6 8 19 6 23 22 11 27 69 100
2022/2023572 76 37 17 58 50 176 47 37 41 5 24 4
2023/2024174 18 44 17 20 14 34 7 5 0 7 8 0
Totale 2.683